Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities - ScienceDirect
Use of everolimus in liver transplantation
Everolimus with Reduced-Dose Calcineurin Inhibitor versus Mycophenolate with Standard-Dose Calcineurin Inhibitor in De Novo Kidney Transplant Recipients: Renal Function Results from the TRANSFORM Study - ATC Abstracts
Pharmacokinetic principles of dose adjustment of mTOR inhibitors in solid organ transplanted patients - Hartinger - 2022 - Journal of Clinical Pharmacy and Therapeutics - Wiley Online Library
Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities | Nefrología
Study design. Steroid dose will be at least 5 mg prednisolone or... | Download Scientific Diagram
Recommendations of everolimus use in liver transplant | Gastroenterología y Hepatología (English Edition)
Frontiers | Low-Dose Everolimus Maintenance Therapy for Renal Angiomyolipoma Associated With Tuberous Sclerosis Complex
Rationale and design of the OPTIMIZE trial: OPen label multicenter randomized trial comparing standard IMmunosuppression with tacrolimus and mycophenolate mofetil with a low exposure tacrolimus regimen In combination with everolimus in de
Recommendations for the use of everolimus in de novo kidney transplantation: False beliefs, myths and realities | Nefrología
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial - The Lancet
An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients - ScienceDirect
Transplantology | Free Full-Text | Dyslipidemia in Renal Transplant Recipients
Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions - ScienceDirect
Everolimus with Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplant Recipients: Efficacy and Safety Outcomes from the TRANSFORM Study - ATC Abstracts
Early conversion of pediatric kidney transplant patients to everolimus with reduced tacrolimus and steroid elimination: Results of a randomized trial - American Journal of Transplantation
Tacrolimus, Sirolimus and Everolimus Doses in HIV-Infected Solid-Organ Recipients, Requiring a Cobicistat-Based Antiretroviral Regimen: Report of Three Cases and Review | SpringerLink
IJMS | Free Full-Text | Prediction of Tacrolimus Exposure by CYP3A5 Genotype and Exposure of Co-Administered Everolimus in Japanese Renal Transplant Recipients
Full article: The use of everolimus in renal-transplant patients
Effect of Early Attainment of Everolimus Target Trough Levels on Efficacy-Safety Outcomes in De Novo Kidney Transplant Recipients: 12-Month Results from US92 and TRANSFORM Studies - ATC Abstracts
Enhanced Humoral Immune Response After COVID-19 Vaccination... : Transplantation
Efficacy and Safety of an Everolimus- vs. a Mycophenolate Mofetil-Based Regimen in Pediatric Renal Transplant Recipients | PLOS ONE
Article: Conversion from tacrolimus to everolimus with complete and early glucocorticoid withdrawal after kidney transplantation: a randomised trial (full text) - January 2018 - NJM
